Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study

Barry Hendin; De Ren Huang; Sibyl Wray; Robert T. Naismith; Sheri Rosenblatt; Javier Zambrano; Brian Werneburg

doi:10.2217/nmt-2016-0032

Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study

Barry Hendin, De Ren Huang, Sibyl Wray, Robert T. Naismith, Sheri Rosenblatt, Javier Zambrano, Brian Werneburg

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.

METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.

RESULTS: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.

CONCLUSION: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.

Original language	English
Pages (from-to)	39-47
Number of pages	9
Journal	Neurodegenerative disease management
Volume	7
Issue number	1
DOIs	https://doi.org/10.2217/nmt-2016-0032
State	Published - Feb 1 2017

Keywords

Delphi
adverse event management
peginterferon β-1a

Access to Document

10.2217/nmt-2016-0032

Cite this

@article{4654739ba4b34c1082655469f3e25bdd,

title = "Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study",

abstract = "AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.RESULTS: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.CONCLUSION: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.",

keywords = "Delphi, adverse event management, peginterferon β-1a",

author = "Barry Hendin and Huang, {De Ren} and Sibyl Wray and Naismith, {Robert T.} and Sheri Rosenblatt and Javier Zambrano and Brian Werneburg",

year = "2017",

month = feb,

day = "1",

doi = "10.2217/nmt-2016-0032",

language = "English",

volume = "7",

pages = "39--47",

journal = "Neurodegenerative disease management",

issn = "1758-2024",

number = "1",

}

TY - JOUR

T1 - Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation

T2 - Delphi analysis of the ALLOW study

AU - Hendin, Barry

AU - Huang, De Ren

AU - Wray, Sibyl

AU - Naismith, Robert T.

AU - Rosenblatt, Sheri

AU - Zambrano, Javier

AU - Werneburg, Brian

PY - 2017/2/1

Y1 - 2017/2/1

N2 - AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.RESULTS: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.CONCLUSION: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.

AB - AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach.METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews.RESULTS: Respondents (n = 37) agreed that the most common ISR, erythema, was not disruptive to daily activities. Patient education, as a conversation with a clinician about ISR potential, was recommended.CONCLUSION: The consensus of Delphi respondents on ISR experience and ISR management after switching from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and manage patient expectations.

KW - Delphi

KW - adverse event management

KW - peginterferon β-1a

UR - http://www.scopus.com/inward/record.url?scp=85050577923&partnerID=8YFLogxK

U2 - 10.2217/nmt-2016-0032

DO - 10.2217/nmt-2016-0032

M3 - Article

C2 - 28071330

AN - SCOPUS:85050577923

SN - 1758-2024

VL - 7

SP - 39

EP - 47

JO - Neurodegenerative disease management

JF - Neurodegenerative disease management

IS - 1

ER -

Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this